Table 3.
Patient | Virology Subtype | RAS in Patient Isolates | VOX EC50 FC From WT | VEL EC50 FC From WT | SOF EC50 FC From WT | ||
---|---|---|---|---|---|---|---|
NS3 | NS5A | NS5B | |||||
1 | Novel GT2 | ND | T24S | None | 0.58 | 1.2 | NR |
2 | Novel GT2 | ND | T24S L31M | None | 0.66 | 1.2 | NR |
3 | Novel GT2 | ND | T24S L31M | None | ND | 22.5 | NR |
4 | Novel GT2 | None | T24S F28C | None | 1.09 | 3.7 | NR |
5 | Novel GT2 | None | T24S L31M | None | 1.37 | 0.125 | NR |
6 | Novel GT2 | None | F28V L31V | M289L | 0.29 | 3.7 | NR |
7 | Novel GT2 | None | T24S L31M | M289L | 1.43 | 0.62 | NR |
8 | Novel GT2 | None | T24S L31M C92T | None | No data | ND | ND |
9 | Novel GT2 | NA | T24S L31M | None | Failed | Failed | NR |
10 | Novel GT4 | None | L30R | None | 1.42 | NR | NR |
11 | Novel GT4 | None | L30R | None | 0.36 | 2 | NR |
12 | Novel GT4 | None | L30R | E237G | 1 | 2 | NR |
13 | Novel GT4 | None | L28V L30H | None | 1.25 | 1 | NR |
14 | Novel GT4 | None | L30R | None | ND | ND | ND |
15 | Novel GT6 | None | F28M | M289L | 1.27 | 3.33 | NR |
16 | Novel GT6 | ND | None | None | ND | 0.67 | NR |
17 | Novel GT1 | I170V | Q30R L31M | None | ND | 1.6 | 1 |
18 | Novel GT3 | ND | A30K | None | ND | ND | ND |
19 | Novel GT5 | No FG coverage in NS3 | Q30S L31M T93S | None | ND | 340 | ND |
Abbreviations: FC, fold change; FG, full genome sequencing; GT, genotype; NA, not applicable due to low sequence coverage; ND, not done due to sample unavailability; NR, no replication; RAS, resistance-associated substitutions; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir; WT, wild-type.